Does the inhibition of renin-angiotensin system decrease inter-dialytic weight gain in anuric hemodialysis patients?

Basit Öğe Kaydı
dc.contributor.authorKutlucan, Ali
dc.contributor.authorDemir, Murat
dc.contributor.authorTürker, Y.
dc.contributor.authorSezer, Mehmet Tuğrul
dc.contributor.authorKutlucan, Leyla
dc.contributor.authorTunç, Neşe
dc.contributor.authorAltuntaş, A.
dc.contributor.authorUgan, Yunus
dc.date.accessioned2020-03-26T19:01:56Z
dc.date.available2020-03-26T19:01:56Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractOBJECTIVE: Knowledge about the inhibition of centrally located angiotensin-I (AT-I) receptors by highly lipophilic AT-I receptor blockers and its' effect are limited with experimental studies. Thus, we aimed to investigate the effect of Telmisartan on Inter-dialytic weight gain (IDWG) % and echocardiographic measurements in anuric hemodialysis (HD) patients. PATIENTS AND METHODS: A total of forty-one anuric HD patients with >= 6 months maintenance on HD were included in this prospective, randomized and self-controlled study. Four weeks prior the study, angiotensin converting enzyme blockers and AT-I receptor blocker drugs were stopped. Patients were assessed three times during the study protocol. These are baseline, three months later (without Telmisartan period) and three months after Telmisartan therapy. RESULTS: IDWG % was significantly decreased in the period of with Telmisartan compared to period without Telmisartan (5.6 +/- 1.0% vs 5.3 +/- 1.0%, p = 0.03). After the administration of Telmisartan left ventricule end-diastolic diameter (LVEDD) (p = 0.001) and inferior vena cava diameter (IVCD) (19.1 +/- 3.8 mm vs 17.3 +/- 4.2 mm, p = 0.001) were significantly decreased compared to the period of without Telmisartan. Despite of significantly changes observed in IVCD and LVEDD measurements in a period without Telmisartan, there was no significantly difference in left ventricular mass index (LVMI) measurements in this period. However, LVMI was significantly regressed after the administration of Telmisartan (269.3 +/- 82.7 g vs 256.3 +/- 70.3 g, p = 0.003 respectively). CONCLUSIONS: Treatment of anuric HD patients with Telmisartan at a dose of 40 mg a day reduces IDWG%, LVEDD and IVCD measurements. Further studies investigating the long-term effect of these beneficial effects on clinical outcomes are necessary.en_US
dc.identifier.endpage76en_US
dc.identifier.issn1128-3602en_US
dc.identifier.issue1en_US
dc.identifier.pmid25635977en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage70en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/32018
dc.identifier.volume19en_US
dc.identifier.wosWOS:000352211700012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherVERDUCI PUBLISHERen_US
dc.relation.ispartofEUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCESen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAngiotensin II receptor antagonisten_US
dc.subjectHemodialysisen_US
dc.subjectInter-dialytic weight gainen_US
dc.subjectInferior vena cava diameteren_US
dc.subjectLeft ventricule mass indexen_US
dc.titleDoes the inhibition of renin-angiotensin system decrease inter-dialytic weight gain in anuric hemodialysis patients?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu